Clinical Trials Logo

BRCA1 Gene Mutation clinical trials

View clinical trials related to BRCA1 Gene Mutation.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05264532 Recruiting - BRCA2 Gene Mutation Clinical Trials

Usefulness of Video-Based Intervention in Helping Participants Encourage Their Families to Get Tested for BRCA Gene Mutations

Start date: April 5, 2018
Phase: N/A
Study type: Interventional

This trial studies how well a video-based intervention works in helping participants encourage their families to get tested for BRCA gene mutations. Testing in families with BRCA gene mutations can allow for risk management and reduction with the overall goal of reducing cancer burden. Video-based intervention sent via text messages may help participants easily share information about BRCA gene mutations with family members.

NCT ID: NCT04294927 Recruiting - Ovarian Cancer Clinical Trials

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

TUBA-WISP-II
Start date: March 1, 2020
Phase: N/A
Study type: Interventional

The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.

NCT ID: NCT04030559 Recruiting - Prostate Carcinoma Clinical Trials

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

Start date: February 25, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well niraparib, when given before surgery, works in treating patients with high risk prostate cancer that has not spread to other parts of the body (localized) and alterations in deoxyribonucleic acid (DNA) repair pathways. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03428802 Recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

Start date: March 8, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab works in treating participants with cancer that has spread to other places in the body, has come back or has spread to nearby tissues or lymph nodes. Monoclonal antibodies such as, pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02993068 Recruiting - HER2/Neu Negative Clinical Trials

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

Start date: April 18, 2017
Phase: N/A
Study type: Interventional

This randomized clinical trial studies how well online genetics educational video with or without pre- and/or post-telephone genetics counseling works in assessing cancer-risk distress in patients with triple negative breast cancer. Online genetic education and telephone genetic counseling may help the doctors learn the stress a person feels about their risk of cancer.

NCT ID: NCT02474264 Recruiting - BRCA2 Gene Mutation Clinical Trials

The Link Between BRCA Mutation and Endothelial Function

Start date: February 2015
Phase: N/A
Study type: Interventional

This study evaluates the effect of BRCA1&2 mutations on cardiovascular diseases by to comparing the endothelial function of male BRCA mutation carriers with that of age matched non-BRCA mutation carriers.

NCT ID: NCT02225015 Recruiting - Breast Cancer Clinical Trials

Cancer Prevention in Women With a BRCA Mutation

Start date: January 2015
Phase: Phase 1
Study type: Interventional

This study aims to develop a follow-up telephone-based genetic counselling (FTGC) intervention for women with a BRCA1 or BRCA2 mutation who have received genetic counseling in the past. Typically, when women undergo genetic testing, they receive standard genetic counselling prior to testing in order to fully understand the procedure and associated implications. If a woman's genetic test results are positive for a mutation, cancer prevention options are then discussed with a counsellor. However, in Canada, there is currently no formal follow-up counselling for women with a BRCA mutation to provide ongoing guidance and support about latest risk reduction strategies. Standard care relies on women making contact for any follow-up questions or concerns they may have. As a result, these women might not have the most current information regarding genetic risk assessment and prevention options. Therefore, individuals are being asked to participate in this study to aid research about the efficacy of FTGC in women with a BRCA mutation.